Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE L DIAZ

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1659318608
CMS profile
301350
Location
LEESBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$7,022.79

117 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE L DIAZ

NPI 1659318608 · CMS profile ID 301350

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

LEESBURG, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659318608?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE L DIAZ, NPI 1659318608, CMS profile ID 301350. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659318608?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSE L DIAZ, NPI 1659318608, CMS profile ID 301350. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659318608?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSE L DIAZ, NPI 1659318608, CMS profile ID 301350, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1659318608?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

117 matching records · $7,022.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 117 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 117.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $16.9206/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685288439 CMS
Grifols USA, LLC $11.5706/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692590805 CMS
Insmed, Inc. $16.9806/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693322559 CMS
GlaxoSmithKline, LLC. $12.0206/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671114991 CMS
Philips Electronics North America Corporation $32.1706/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684074123 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.2106/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072241 CMS
Electromed, Inc. $10.7706/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705239633 CMS
Mylan Specialty L.P. $22.8806/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694785389 CMS
GlaxoSmithKline, LLC. $13.1706/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670331163 CMS
GlaxoSmithKline, LLC. $8.9906/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670848069 CMS
GlaxoSmithKline, LLC. $8.6805/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671259273 CMS
AstraZeneca Pharmaceuticals LP $12.0405/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685035013 CMS
GlaxoSmithKline, LLC. $13.3005/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671395843 CMS
Insmed, Inc. $18.2005/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693318985 CMS
GlaxoSmithKline, LLC. $4.5305/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671358199 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.2105/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072243 CMS
Mylan Specialty L.P. $18.2105/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694810599 CMS
Boston Scientific Corporation $13.7405/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662877425 CMS
Electromed, Inc. $9.8704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705239621 CMS
Genentech USA, Inc. $13.9904/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681293573 CMS
GlaxoSmithKline, LLC. $9.8904/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671437575 CMS
GlaxoSmithKline, LLC. $8.3304/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670337485 CMS
GlaxoSmithKline, LLC. $0.4204/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670980955 CMS
GlaxoSmithKline, LLC. $13.2204/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671134501 CMS
Philips Electronics North America Corporation $31.5004/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684074165 CMS
GlaxoSmithKline, LLC. $9.5504/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670333267 CMS
Grifols USA, LLC $14.0004/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692605897 CMS
AstraZeneca Pharmaceuticals LP $13.6604/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685981371 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.6304/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072245 CMS
GlaxoSmithKline, LLC. $14.9904/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671438731 CMS
Philips Electronics North America Corporation $24.9504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684074163 CMS
Electromed, Inc. $10.4104/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705239629 CMS
Mylan Specialty L.P. $17.0104/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694782461 CMS
Genentech USA, Inc. $18.8404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681282319 CMS
GlaxoSmithKline, LLC. $8.2304/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670584747 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1704/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072247 CMS
AstraZeneca Pharmaceuticals LP $21.0003/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685685429 CMS
Mylan Specialty L.P. $18.5703/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694807765 CMS
GlaxoSmithKline, LLC. $7.7703/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670592789 CMS
GlaxoSmithKline, LLC. $12.1203/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671507151 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.4203/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072249 CMS
Sunovion Pharmaceuticals Inc. $13.8203/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688032531 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.0403/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072251 CMS
GlaxoSmithKline, LLC. $7.0602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671420801 CMS
Philips Electronics North America Corporation $31.9602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684074089 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.3302/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700072253 CMS
Cook Medical LLC $12.1502/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630352393 CMS
Cook Medical LLC $40.1802/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630352395 CMS
Genentech USA, Inc. $19.6502/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681310701 CMS
GlaxoSmithKline, LLC. $17.4902/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671462733 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,022.79 117
PY2020 $28,981.20 105
PY2021 $33,562.98 136
PY2022 $34,307.04 161
PY2023 $26,919.30 127
PY2024 $12,396.09 157
PY2025 $10,106.44 223

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,014.38 14
PY2025 Principal investigator $2,162,389.35 418
PY2024 Principal investigator $5,152,351.03 595
PY2023 Principal investigator $2,944,816.50 319
PY2022 Principal investigator $335,636.65 82
PY2021 Principal investigator $221,254.36 48
PY2020 Principal investigator $34,217.67 9
PY2019 Principal investigator $197,329.08 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

432 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,497.88 12/31/2025 Non-covered Recipient Entity
Clinical Site Partners, LLC dba Flourish Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929314
Principal investigator 1 Merck Sharp & Dohme LLC $367.20 12/31/2025 Non-covered Recipient Entity
Clinical Site Partners, LLC dba Flourish Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929316
Principal investigator 1 ModernaTX, Inc. $663.00 12/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977681
Principal investigator 1 GlaxoSmithKline, LLC. $4,758.82 12/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192189088
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588190
Principal investigator 1 Genentech, Inc. $1,575.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588195
Principal investigator 1 Genentech, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588200
Principal investigator 1 Genentech, Inc. $200.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588212
Principal investigator 1 Genentech, Inc. $300.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588221
Principal investigator 1 Genentech, Inc. $200.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588224
Principal investigator 1 Genentech, Inc. $79.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588229
Principal investigator 1 Genentech, Inc. $325.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588234
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588238
Principal investigator 1 Genentech, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588241
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588246
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588250
Principal investigator 1 Genentech, Inc. $350.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588258
Principal investigator 1 Genentech, Inc. $950.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588262
Principal investigator 1 Genentech, Inc. $1,575.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588266
Principal investigator 1 Genentech, Inc. $200.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588270
Principal investigator 1 Genentech, Inc. $250.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588274
Principal investigator 1 Genentech, Inc. $150.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588277
Principal investigator 1 Genentech, Inc. $83.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588283
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588286
Principal investigator 1 Genentech, Inc. $100.00 12/19/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588299
Principal investigator 1 ModernaTX, Inc. $5,157.36 12/19/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977725
Principal investigator 1 ModernaTX, Inc. $27,213.16 12/19/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977737
Principal investigator 1 ModernaTX, Inc. $9,638.48 12/19/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977753
Principal investigator 1 Genentech, Inc. $248.00 12/18/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588501
Principal investigator 1 ModernaTX, Inc. $255.30 12/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977601
Principal investigator 1 ModernaTX, Inc. $1,824.00 12/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977633
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977755
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,694.00 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803672
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,074.00 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803674
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $700.00 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803676
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $725.00 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803678
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $768.10 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803682
Principal investigator 1 Merck Sharp & Dohme LLC $138,590.30 12/15/2025 Non-covered Recipient Entity
Clinical Site Partners, LLC dba Flourish Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929312
Principal investigator 1 Genentech, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588205
Principal investigator 1 Genentech, Inc. $800.00 12/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588216
Principal investigator 1 Genentech, Inc. $83.00 12/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588289
Principal investigator 1 Genentech, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588292
Principal investigator 1 Genentech, Inc. $125.00 12/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588309
Principal investigator 1 ModernaTX, Inc. $150.00 12/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977641
Principal investigator 1 ModernaTX, Inc. $255.30 12/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977695
Principal investigator 1 ModernaTX, Inc. $11,250.00 12/10/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977595
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/10/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977597
Principal investigator 1 ModernaTX, Inc. $500.00 12/10/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977693
Principal investigator 1 ModernaTX, Inc. $262.20 12/10/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977757
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/10/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977759
Principal investigator 1 ModernaTX, Inc. $456.00 12/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977675
Principal investigator 1 ModernaTX, Inc. $729.30 12/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977727
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677489
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677491
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677493
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677495
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677497
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677499
Principal investigator 1 ModernaTX, Inc. $6,165.12 11/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977579
Principal investigator 1 ModernaTX, Inc. $682.50 11/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977587
Principal investigator 1 ModernaTX, Inc. $4,638.72 11/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977593
Principal investigator 1 ModernaTX, Inc. $11,513.26 11/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977733
Principal investigator 1 GlaxoSmithKline, LLC. $3,844.03 11/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192187165
Principal investigator 1 Genentech, Inc. $3,602.00 11/21/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211588153
Principal investigator 1 GlaxoSmithKline, LLC. $14,871.00 11/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189084
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $188.20 11/20/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803670
Principal investigator 1 GlaxoSmithKline, LLC. $564.00 11/20/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192098434
Principal investigator 1 ModernaTX, Inc. $66.30 11/20/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977659
Principal investigator 1 Genentech, Inc. $3,125.00 11/14/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588148
Principal investigator 1 Genentech, Inc. $100.00 11/14/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588161
Principal investigator 1 Genentech, Inc. $100.00 11/14/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588172
Principal investigator 1 Genentech, Inc. $83.00 11/14/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588181
Principal investigator 1 GlaxoSmithKline, LLC. $58.75 11/14/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188180
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,683.85 11/13/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803666
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $545.00 11/13/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803668
Principal investigator 1 GlaxoSmithKline, LLC. $90.00 11/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192098441
Principal investigator 1 GlaxoSmithKline, LLC. $786.00 11/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192098447
Principal investigator 1 GlaxoSmithKline, LLC. $442.00 11/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192188185
Principal investigator 1 ModernaTX, Inc. $500.00 11/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007239
Principal investigator 1 Genentech, Inc. $3,150.00 11/12/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588168
Principal investigator 1 GlaxoSmithKline, LLC. $35,095.50 11/12/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150128
Principal investigator 1 GlaxoSmithKline, LLC. $597.00 11/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192187148
Principal investigator 1 ModernaTX, Inc. $134.42 11/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977613
Principal investigator 1 ModernaTX, Inc. $1,938.00 11/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977661
Principal investigator 1 ModernaTX, Inc. $654.94 11/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977711
Principal investigator 1 Genentech, Inc. $950.00 11/07/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588165
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/05/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798245
Principal investigator 1 ModernaTX, Inc. $5,070.00 11/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977619
Principal investigator 1 ModernaTX, Inc. $5,016.00 11/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977667
Principal investigator 1 ModernaTX, Inc. $2,386.80 11/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977683
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677477
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677479
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677481
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677483
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677485
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677487
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $38,019.00 10/29/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803662
Principal investigator 1 Genentech, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588076
Principal investigator 1 Genentech, Inc. $225.00 10/29/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588093
Principal investigator 1 Genentech, Inc. $83.00 10/29/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588122
Principal investigator 1 Genentech, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588140
Principal investigator 1 ModernaTX, Inc. $464.10 10/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977591
Principal investigator 1 ModernaTX, Inc. $910.00 10/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977663
Principal investigator 1 ModernaTX, Inc. $1,938.00 10/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977673
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 10/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677501
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 10/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677503
Principal investigator 1 ModernaTX, Inc. $6,066.32 10/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977617
Principal investigator 1 ModernaTX, Inc. $9,664.00 10/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977743
Principal investigator 1 ModernaTX, Inc. $654.94 10/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977631
Principal investigator 1 ModernaTX, Inc. $928.20 10/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977657
Principal investigator 1 GlaxoSmithKline, LLC. $7,350.00 10/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192185500
Principal investigator 1 Genentech, Inc. $3,369.00 10/21/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211588060
Principal investigator 1 GlaxoSmithKline, LLC. $840.02 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188166
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,752.00 10/08/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803664
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.00 10/08/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187156
Principal investigator 1 ModernaTX, Inc. $2,622.00 10/08/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977719
Principal investigator 1 GlaxoSmithKline, LLC. $11,814.30 10/06/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150147
Principal investigator 1 GlaxoSmithKline, LLC. $7,459.12 10/02/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188171
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677463
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677465
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677467
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677469
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677471
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677473
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677475
Principal investigator 1 ModernaTX, Inc. $5,473.52 09/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977623
Principal investigator 1 ModernaTX, Inc. $8,117.76 09/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977625
Principal investigator 1 ModernaTX, Inc. $1,099.77 09/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977749
Principal investigator 1 ModernaTX, Inc. $7,471.17 09/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007225
Principal investigator 1 Genentech, Inc. $125.00 09/26/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588046
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677457
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677459
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 09/24/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677461
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 09/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187152
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,063.00 09/18/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803658
Principal investigator 1 ModernaTX, Inc. $7,587.45 09/15/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977573
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/15/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977735
Principal investigator 1 ModernaTX, Inc. $9,273.55 09/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977723
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,760.00 09/10/2025 Non-covered Recipient Entity
Pulmonary Group Of Central Florida, Llc
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235994425
Principal investigator 1 GlaxoSmithKline, LLC. $22,217.40 09/10/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150133
Principal investigator 1 ModernaTX, Inc. $600.00 09/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977639
Principal investigator 1 ModernaTX, Inc. $255.30 09/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977643
Principal investigator 1 ModernaTX, Inc. $2,097.60 09/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977751
Principal investigator 1 AstraZeneca Pharmaceuticals LP $59,937.89 09/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC DBA FLOURISH RESEARCH
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185543164
Principal investigator 1 GlaxoSmithKline, LLC. $10,932.26 09/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188189
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $465.70 09/02/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803660
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677429
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677431
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677433
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677435
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677437
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677453
Principal investigator 1 ModernaTX, Inc. $15,396.78 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977577
Principal investigator 1 ModernaTX, Inc. $837.33 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977647
Principal investigator 1 ModernaTX, Inc. $6,066.32 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977671
Principal investigator 1 ModernaTX, Inc. $9,638.48 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977691
Principal investigator 1 ModernaTX, Inc. $7,731.20 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977715
Principal investigator 1 ModernaTX, Inc. $158.08 08/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007205
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,929.00 08/18/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803656
Principal investigator 1 GlaxoSmithKline, LLC. $3,560.87 08/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192187145
Principal investigator 1 GlaxoSmithKline, LLC. $37,351.40 08/11/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150141
Principal investigator 1 GlaxoSmithKline, LLC. $6,070.00 08/08/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188198
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,335.00 08/07/2025 Non-covered Recipient Entity
Clinical Site Partners - Leesburg
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS No dispute reported 06/30/2026 1211587954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 08/06/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803652
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,258.00 08/06/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803654
Principal investigator 1 Genentech, Inc. $1,123.00 08/05/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211588043
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677419
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677421
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677423
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677425
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677427
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 08/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803650
Principal investigator 1 Genentech, Inc. $853.00 08/01/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588039
Principal investigator 1 GlaxoSmithKline, LLC. $221.00 08/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192188194
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803610
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,275.40 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803612
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,852.60 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803614
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $353.58 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803616
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $120.17 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803618
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,605.47 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803620
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $880.00 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803622
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,053.70 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803624
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $106.48 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803626
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $140.00 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803628
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803630
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $124.05 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803632
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $614.50 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803634
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803636
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,488.20 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803638
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $128.27 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803640
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $394.96 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803642
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,074.90 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803644
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $125.88 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803646
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $746.96 07/31/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803648
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,212.45 07/30/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803608
Principal investigator 1 ModernaTX, Inc. $1,521.52 07/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977649
Principal investigator 1 ModernaTX, Inc. $8,798.16 07/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977739
Principal investigator 1 GlaxoSmithKline, LLC. $398.00 07/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192187140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,852.00 07/09/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803606
Principal investigator 1 GlaxoSmithKline, LLC. $11,539.80 07/09/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150137
Principal investigator 1 GlaxoSmithKline, LLC. $19,625.00 07/02/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187160
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 07/02/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192187169
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677439
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677441
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677443
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677445
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677447
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677449
Principal investigator 1 Genentech, Inc. $2,112.00 07/01/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588025
Principal investigator 1 ModernaTX, Inc. $9,897.93 06/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977575
Principal investigator 1 ModernaTX, Inc. $4,090.32 06/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977627
Principal investigator 1 ModernaTX, Inc. $837.33 06/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977629
Principal investigator 1 ModernaTX, Inc. $3,479.04 06/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,434.00 06/25/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803604
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677415
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677417
Principal investigator 1 ModernaTX, Inc. $17,781.76 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977615
Principal investigator 1 ModernaTX, Inc. $30,793.56 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977717
Principal investigator 1 ModernaTX, Inc. $5,868.72 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977745
Principal investigator 1 ModernaTX, Inc. $2,093.30 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007199
Principal investigator 1 GlaxoSmithKline, LLC. $63,705.60 06/13/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192150145
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,500.00 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC DBA FLOURISH RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185543162
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,148.00 06/11/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803602
Principal investigator 1 ModernaTX, Inc. $388.80 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977773
Principal investigator 1 ModernaTX, Inc. $607.50 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977775
Principal investigator 1 ModernaTX, Inc. $1,215.00 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977777
Principal investigator 1 ModernaTX, Inc. $607.50 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977785
Principal investigator 1 ModernaTX, Inc. $1,181.25 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977787
Principal investigator 1 ModernaTX, Inc. $38,137.50 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977795
Principal investigator 1 ModernaTX, Inc. $405.00 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977797
Principal investigator 1 ModernaTX, Inc. $276.75 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977811
Principal investigator 1 ModernaTX, Inc. $364.50 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977813
Principal investigator 1 ModernaTX, Inc. $225.00 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977815
Principal investigator 1 ModernaTX, Inc. $72,326.80 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977825
Principal investigator 1 ModernaTX, Inc. $978.75 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977827
Principal investigator 1 ModernaTX, Inc. $17,361.00 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977843
Principal investigator 1 ModernaTX, Inc. $80,097.70 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977847
Principal investigator 1 ModernaTX, Inc. $978.75 06/11/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977849
Principal investigator 1 Genentech, Inc. $200.00 06/02/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588374
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677393
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677395
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677397
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677399
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677401
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677403
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677405
Principal investigator 1 ModernaTX, Inc. $26,286.08 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977583
Principal investigator 1 ModernaTX, Inc. $1,350.00 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977637
Principal investigator 1 ModernaTX, Inc. $5,730.40 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977713
Principal investigator 1 ModernaTX, Inc. $15,396.78 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977721
Principal investigator 1 ModernaTX, Inc. $2,922.00 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007189
Principal investigator 1 ModernaTX, Inc. $15,909.08 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007191
Principal investigator 1 ModernaTX, Inc. $5,275.92 05/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007233
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677409
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 05/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677411
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 05/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677413
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $810.00 05/27/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803600
Principal investigator 1 GlaxoSmithKline, LLC. $5,694.85 05/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192185504
Principal investigator 1 ModernaTX, Inc. $81,859.75 05/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977783
Principal investigator 1 SANOFI PASTEUR INC. $90.00 05/15/2025 Non-covered Recipient Entity
Clinical Site Partners Llc Csp Orlando
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226089712
Principal investigator 1 SANOFI PASTEUR INC. $280.00 05/15/2025 Non-covered Recipient Entity
Clinical Site Partners Llc Csp Orlando
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226089717
Principal investigator 1 SANOFI PASTEUR INC. $1,325.00 05/15/2025 Non-covered Recipient Entity
Clinical Site Partners Llc Csp Orlando
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226089755
Principal investigator 1 ModernaTX, Inc. $150,000.00 05/09/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977841
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677381
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677383
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677385
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677387
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677389
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677391
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,243.32 05/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803598
Principal investigator 1 Genentech, Inc. $2,059.00 05/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588480
Principal investigator 1 ModernaTX, Inc. $29,765.12 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977585
Principal investigator 1 ModernaTX, Inc. $5,572.32 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977607
Principal investigator 1 ModernaTX, Inc. $6,659.12 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007193
Principal investigator 1 ModernaTX, Inc. $16,071.00 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007207
Principal investigator 1 ModernaTX, Inc. $418.66 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007223
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 04/23/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677407
Principal investigator 1 GlaxoSmithKline, LLC. $8,969.59 04/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192188176
Principal investigator 1 ModernaTX, Inc. $1,259.70 04/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977567
Principal investigator 1 ModernaTX, Inc. $327.47 04/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977605
Principal investigator 1 ModernaTX, Inc. $95.81 04/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977679
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,494.00 04/11/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803596
Principal investigator 1 AstraZeneca UK Limited $636.66 04/08/2025 Non-covered Recipient Entity
FLOURISH RESEARCH LEESBURG
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185543156
Principal investigator 1 GlaxoSmithKline, LLC. $8,124.72 04/02/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192189080
Principal investigator 1 ModernaTX, Inc. $1,386.45 04/02/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677369
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677371
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677373
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677375
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677377
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677379
Principal investigator 1 Genentech, Inc. $225.00 04/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588358
Principal investigator 1 Genentech, Inc. $125.00 04/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588392
Principal investigator 1 Genentech, Inc. $83.00 04/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588400
Principal investigator 1 Genentech, Inc. $83.00 04/01/2025 Non-covered Recipient Entity
Clinical Site Partners LLC dba CSP Leesburg
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588439
Principal investigator 1 ModernaTX, Inc. $80.60 04/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007211
Principal investigator 1 ModernaTX, Inc. $3,931.20 04/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007229
Principal investigator 1 ModernaTX, Inc. $200.00 03/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977769
Principal investigator 1 ModernaTX, Inc. $1,400.00 03/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007197
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007203
Principal investigator 1 ModernaTX, Inc. $7,000.00 03/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007213
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33,301.00 03/24/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803594
Principal investigator 1 ModernaTX, Inc. $22,420.48 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977569
Principal investigator 1 ModernaTX, Inc. $5,117.84 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977611
Principal investigator 1 ModernaTX, Inc. $17,367.04 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977747
Principal investigator 1 ModernaTX, Inc. $6,263.92 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007195
Principal investigator 1 ModernaTX, Inc. $5,844.00 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007219
Principal investigator 1 ModernaTX, Inc. $10,466.50 03/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007237
Principal investigator 1 ModernaTX, Inc. $1,524.90 03/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977655
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677329
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677331
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677333
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677335
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677337
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677339
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677341
Principal investigator 1 ModernaTX, Inc. $39,563.52 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977571
Principal investigator 1 ModernaTX, Inc. $3,210.63 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977589
Principal investigator 1 ModernaTX, Inc. $20,823.40 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977621
Principal investigator 1 ModernaTX, Inc. $6,125.60 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977677
Principal investigator 1 ModernaTX, Inc. $22,033.92 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977685
Principal investigator 1 ModernaTX, Inc. $22,794.24 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977707
Principal investigator 1 ModernaTX, Inc. $4,149.60 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977729
Principal investigator 1 ModernaTX, Inc. $6,283.68 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007221
Principal investigator 1 ModernaTX, Inc. $7,305.00 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007227
Principal investigator 1 ModernaTX, Inc. $7,117.22 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007231
Principal investigator 1 ModernaTX, Inc. $2,082.20 02/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007235
Principal investigator 1 ModernaTX, Inc. $144.90 02/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977687
Principal investigator 1 ModernaTX, Inc. $75.00 02/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977699
Principal investigator 1 ModernaTX, Inc. $198.72 02/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977703
Principal investigator 1 ModernaTX, Inc. $262.20 02/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977765
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677355
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677357
Principal investigator 1 Boehringer Ingelheim International GmbH $331.65 02/25/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677359
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 02/25/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677361
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 02/25/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677363
Principal investigator 1 GlaxoSmithKline, LLC. $3,436.71 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192185495
Principal investigator 1 ModernaTX, Inc. $1,300.00 02/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977599
Principal investigator 1 ModernaTX, Inc. $750.00 02/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977689
Principal investigator 1 ModernaTX, Inc. $9,638.48 02/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977603
Principal investigator 1 ModernaTX, Inc. $1,467.45 02/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977791
Principal investigator 1 GlaxoSmithKline, LLC. $7,728.96 02/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192185509
Principal investigator 1 SANOFI PASTEUR INC. $3,526.25 02/03/2025 Non-covered Recipient Entity
Clinical Site Partners Llc Csp Orlando
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226089655
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677317
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677319
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677321
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677323
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677325
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677327
Principal investigator 1 ModernaTX, Inc. $525.00 01/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977763
Principal investigator 1 ModernaTX, Inc. $600.00 01/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977767
Principal investigator 1 ModernaTX, Inc. $120.00 01/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977845
Principal investigator 1 SANOFI PASTEUR INC. $2,100.00 01/29/2025 Non-covered Recipient Entity
Clinical Site Partners Llc Csp Orlando
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226089661
Principal investigator 1 Genentech, Inc. $100.00 01/28/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587986
Principal investigator 1 Genentech, Inc. $79.00 01/28/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211588007
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677343
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677345
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677347
Principal investigator 1 Boehringer Ingelheim International GmbH $22.11 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677349
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677351
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 01/27/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677353
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,860.00 01/27/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803590
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $343.00 01/27/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803592
Principal investigator 1 ModernaTX, Inc. $3,210.63 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977581
Principal investigator 1 ModernaTX, Inc. $12,369.92 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977609
Principal investigator 1 ModernaTX, Inc. $25,628.80 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977635
Principal investigator 1 ModernaTX, Inc. $31,477.76 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977665
Principal investigator 1 ModernaTX, Inc. $1,204.81 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977701
Principal investigator 1 ModernaTX, Inc. $2,311.92 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977705
Principal investigator 1 ModernaTX, Inc. $3,280.16 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977731
Principal investigator 1 ModernaTX, Inc. $24,727.20 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977741
Principal investigator 1 ModernaTX, Inc. $4,383.00 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007201
Principal investigator 1 ModernaTX, Inc. $4,505.28 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007209
Principal investigator 1 ModernaTX, Inc. $23,945.30 01/27/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007215
Principal investigator 1 ModernaTX, Inc. $2,097.60 01/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977645
Principal investigator 1 ModernaTX, Inc. $1,021.20 01/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977697
Principal investigator 1 ModernaTX, Inc. $1,159.20 01/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ?50 Years of Age No dispute reported 06/30/2026 1252977761
Principal investigator 1 ModernaTX, Inc. $47.19 01/22/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977669
Principal investigator 1 ModernaTX, Inc. $66.30 01/22/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977709
Principal investigator 1 ModernaTX, Inc. $4,725.00 01/22/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977771
Principal investigator 1 ModernaTX, Inc. $80.00 01/22/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977799
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,357.00 01/17/2025 Non-covered Recipient Entity
Clinical Site Partners LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220803588
Principal investigator 1 ModernaTX, Inc. $160.00 01/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977807
Principal investigator 1 ModernaTX, Inc. $2,808.00 01/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977817
Principal investigator 1 ModernaTX, Inc. $300.00 01/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977851
Recipient GlaxoSmithKline, LLC. $124.16 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154052
Recipient GlaxoSmithKline, LLC. $46.76 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154056
Recipient GlaxoSmithKline, LLC. $53.88 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154061
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154066
Recipient GlaxoSmithKline, LLC. $62.49 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154070
Recipient GlaxoSmithKline, LLC. $369.60 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154074
Recipient GlaxoSmithKline, LLC. $38.53 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154079
Recipient GlaxoSmithKline, LLC. $79.69 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154083
Recipient GlaxoSmithKline, LLC. $264.84 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154086
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192154090
Recipient GlaxoSmithKline, LLC. $50.41 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192159395
Recipient GlaxoSmithKline, LLC. $45.71 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192159399
Recipient GlaxoSmithKline, LLC. $232.00 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192159403
Recipient GlaxoSmithKline, LLC. $59.81 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192159407
Principal investigator 1 ModernaTX, Inc. $68.30 01/15/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS - LEESBURG
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252977653
Principal investigator 1 ModernaTX, Inc. $1,750.00 01/15/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977789
Principal investigator 1 ModernaTX, Inc. $600.00 01/15/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977829
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 01/10/2025 Non-covered Recipient Entity
MATRIX CLINICAL RESEARCHINC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192154048
Principal investigator 1 Genentech, Inc. $4,711.00 01/09/2025 Non-covered Recipient Entity
Clinical Site Partners - Orlando
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211588013
Principal investigator 1 AstraZeneca UK Limited $59,365.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC DBA FLOURISH RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185543159
Principal investigator 1 ModernaTX, Inc. $1,386.45 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977779
Principal investigator 1 ModernaTX, Inc. $11,232.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977781
Principal investigator 1 ModernaTX, Inc. $1,386.45 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977793
Principal investigator 1 ModernaTX, Inc. $75.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977801
Principal investigator 1 ModernaTX, Inc. $500.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977803
Principal investigator 1 ModernaTX, Inc. $1,386.45 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977805
Principal investigator 1 ModernaTX, Inc. $375.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977809
Principal investigator 1 ModernaTX, Inc. $480.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977819
Principal investigator 1 ModernaTX, Inc. $600.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977823
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977831
Principal investigator 1 ModernaTX, Inc. $5,616.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977833
Principal investigator 1 ModernaTX, Inc. $350.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977835
Principal investigator 1 ModernaTX, Inc. $276.75 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977837
Principal investigator 1 ModernaTX, Inc. $600.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977839
Principal investigator 1 ModernaTX, Inc. $100.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977853
Principal investigator 1 ModernaTX, Inc. $400.00 01/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252977855
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677307
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677309
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677311
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677313
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677315
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677365
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Medical Research Of Central Florida
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220677367